Celltheon builds biotech technology platforms and delivers end-to-end solutions that bridge early drug development and manufacturing.
Services
Antibody-drug
conjugates
Antibody: targets tumor antigen with high specificity
Linker: controls release in tumor environment.
Payload: potent cytotoxin that kills cancer cells
Overview
The ideal CHO media system — synthesized from leading commercial platforms
Antibody-Drug Conjugates (ADCs) are a class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads, connected via a stable chemical linker.
- Rapidly expanding pipeline across solid tumors & hematologic cancers
- Complex structure demands expert development partners
- 14+ FDA-approved ADCs for oncology indications
- Precision targeting minimizes off-tumor toxicity
GOLDILOCKS™ system
& components
-
Target Validation
& Antibody Development- Target expression profiling
- Internalization assessment
- Antibody optimization & characterization
- High-titer production via OmniCHO™
-
Linker-Payload
Development- Payload selection by mechanism & potency
- Linker chemistry optimization
- Stability & release profiling
- Full linker-payload characterization
-
Conjugation & Manufacturing
- Random or site-specific methods
- DAR optimization
- Complete analytical characterization
- GLP-grade material production
-
Functional
Assessment- Binding & internalization studies
- Cytotoxicity across 4 cell lines
- Mechanism of action confirmation
- Developability risk profiling
Package options
Service tiers built for screening-to-IND workflows, with flexible packages and full documentation
All packages include comprehensive data reports suitable for regulatory submissions. A la carte and custom configurations are available.
-
Talk to a ScientistDiscovery stage
Early Screening
What you get:
- mAb cloning, transfection, purification & QC
- Conjugation, purification & formulation
- DAR analysis, Free LP, SE-HPLC, SDS-PAGE
Ideal for: Screening multiple payloads, linkers, or Ab variants to identify promising candidates
-
Talk to a ScientistLead optimization
Focused Characterization
What you get:
- Full antibody production & QC
- Plasma stability & aggregation analytics
- Internalization kinetics (4 cell lines)
Ideal for: Narrowing hits to leads; requires stability data and developability ask assessment
-
Talk to a ScientistPreclinical / ind-enabling
IND-ready Package
What you get:
- Full biochemical profiling
- Potency & cytotoxicity testing
- GLP-grade material production
Ideal for: Late-stage programs requiring comprehensive profiling for IND-enabling studies
Conjugation technologies & methods
Celltheon supports both conventional and advanced site-specific conjugation strategies. Our experts guide payload and chemistry selection based on target biology, desired DAR, and program stage.
-
Lysine Conjugation
Classical NHS ester chemistry; stochastic; broad IgG compatibility
-
Cysteine Conjugation
Reduced interchain disulfides; DAR 2–8; well-validated in clinical ADCs
-
Site-Specific (Engineered)
THIOMAB, enzymatic, or non-natural amino acid incorporation for homogeneous DAR
-
Site Specific (Non-engineered)
Celltheon’s Trident™ site-specific conjugation enzyme targets all mAbs without protein engineering
-
Click Chemistry (DBCO/Azide)
Bioorthogonal; high selectivity; compatible with diverse payloads
-
Affinity-Based Conjugation
F-binding adaptor proteins guide payload placement without protein engineering
-
Oxime / Biorthogonal
Ketone/aldehyde handles; stable oxime bond; excellent for glycan-based sites
-
Bifunctional Linker Approaches
Flexible bridging strategies for novel scaffold or protein-drug conjugates
Analytics & Characterization
Designed for difficult molecules, complex formats, and scale-up certainty
Comprehensive in-house analytics spanning DAR confirmation, purity, stability, and functional potency — supporting every stage from screening to IND submission.
-
DAR & Purity
DAR by HIC-HPLC and intact MS. SE-HPLC monomer/aggregate content. Reduced + non-reducing CE-SDS. Charge variant analysis. Peptide mapping for conjugation site ID.
-
Stability
Plasma stability (human + mouse). DAR stability over time. Aggregation + free drug quantification. Freeze-thaw cycling. Concentrated stability assessment.
-
Biophysical
Thermal stability (Tm/Tagg via DSF/DLS). Colloidal stability + hydrodynamic radius. Secondary structure (CD spectroscopy). Intact mass MS + glycoform profiling. Polyreactivity + aggregation propensity.
-
Functional / Potency
Internalization kinetics across multiple cell lines. Cytotoxicity (target +/- lines). Binding + Fc receptor affinity (SPR/BLI). Mechanism-of-action confirmation. Cell-based binding potency (ELISA).
Frequently Asked Questions
Quick answers
Quick answers
to common questions
Quick answers about timelines, quality, and how to work with Celltheon.
We support biotech and biopharma teams from discovery through preclinical development and manufacturing readiness.
Our offering spans DNA, protein production, engineering, developability, assays, stable cell lines, conjugation, and process development.
Both. Programs can use an integrated workflow or select the individual services and technologies they need.
Yes. Choose platform transfer to your team or a service model executed by Celltheon scientists.
We begin with your goals, molecule, timeline, and deliverables, then provide a clear technical plan and project scope.
We share relevant case studies, quality documentation, platform data, and a project-specific package aligned with your requirements.
